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Abstract
Background: As patients with left ventricular assist device (LVAD) have long expected survival, the incidence of
noncardiac surgery in this patient population is increasing. Here, we present the anesthetic management of a
patient with a continuous-flow LVAD who underwent video-assisted thoracic surgery (VATS).
Case presentation: A 37-year-old man with LVAD was scheduled to undergo VATS because of repeated
spontaneous pneumothorax. Generally, patients with these devices have marginal right heart function; therefore, it
is important to avoid factors that worsen pulmonary vascular resistance (PVR). However, VATS requires one-lung
ventilation (OLV) and it tends to cause increase in PVR, leading to right heart failure.
In the present case, when the patient was set in a lateral decubitus position and progressive hypoxia was observed
during OLV, transesophageal echocardiography demonstrated a dilated right ventricle and a temporally flattened
interventricular septum, and the central venous pressure increased to approximately 20 mmHg. Because we
anticipated deterioration of right heart function, dobutamine and milrinone were administered and/or respirator
settings were changed to decrease PVR for maintaining LVAD performance. Finally, resection of a bulla was
completed, and the patient was discharged in stable condition on postoperative day 37.
Conclusions: The anesthetic management of a patient with LVAD during VATS is challenging because the possible
hemodynamic changes induced by hypoxia associated with OLV affect LVAD performance and right heart function.
In our experience, VATS that requires OLV will be well tolerated in a patient with LVAD with preserved right heart
function, and a multidisciplinary approach to maintain right heart function will be needed.
Keywords: One-lung ventilation, Left ventricular assist device, Transesophageal echocardiography, Pneumothorax,
Video-assisted thoracoscopic surgery
Background
Left ventricular assist devices (LVADs) are gaining popu-
larity as a viable treatment, and patients with LVADs
survive for many years; consequently, such patients who
require noncardiac surgery are becoming increasingly
common [1, 2]. The management of LVAD-supported pa-
tients for noncardiac surgery presents many challenges,
and case reports of patients with LVADs who underwent
several different types of noncardiac surgeries have been
published [3–10]. However, none of these cases reported
the perioperative management of video-assisted thoracic
surgery (VATS). Here, we present the case of a patient
with a continuous-flow LVAD in whom VATS and resec-
tion of a bulla were successfully completed.
Case presentation
A 37-year-old man (weight 61 kg, height 183 cm) was
diagnosed with Becker muscular dystrophy-associated
cardiomyopathy. Eventually, he received implantation of
EVAHEART® (Sun Medical Technology Research Corpor-
ation, Nagano, Japan), which is an implantable centrifugal
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LVAD, in addition to tricuspid annuloplasty (TAP) and pa-
tent foramen ovale closure surgery. One month later and 2
months after LVAD implantation, he developed spontan-
eous right-sided pneumothorax. Chest radiography and
computed tomography (CT) revealed right-sided pneumo-
thorax (Figs. 1 and 2, respectively). Moreover, bullae of the
right pulmonary apex with moderately retained pleural
effusion were observed on CT images. Subsequently, the
patient was scheduled for VATS.
Prior to surgery, the patient’s body weight decreased
due to loss of appetite. He was hydrated with crystalloids
at the request of the cardiac surgery team to prevent
occurrence of the sucking phenomenon and the forma-
tion of thrombi. Consequently, he gained 3.5 kg of body
weight in 4 days, exceeding his target body weight by 1
kg. However, a preoperative chest radiograph showed a
dilated cardiac shadow and pulmonary congestion. The
patient was routinely administered aspirin (100 mg) each
day and warfarin to maintain the prothrombin time-
international normalized ratio (PT-INR) at approximately
2.5–3.5 for systemic anticoagulation. The patient bridged
from warfarin to intravenous heparin 3 days preopera-
tively. On the day of the operation, heparin administration
was discontinued 3 h before surgery. Routine laboratory
test results were within the normal limits except for
anemia and coagulation abnormalities: prothrombin time:
17 s, activated partial thromboplastin time (APTT): 52.9 s
(APTT control: 32.9 s), and PT-INR: 1.51.
The patient was transported to the operating room,
and monitors were placed according to the Standard
American Society of Anesthesiologists. An arterial cath-
eter was inserted in the left radial artery before general
anesthesia induction using an ultrasound-guided tech-
nique. The pump speed was set at 1700 rpm, pump
power consumption was 2.8W, and the mean arterial
blood pressure (ABP) was approximately 80 mmHg.
Anesthetic induction was achieved with midazolam 2
mg, remifentanil 0.2 μg/kg/min, and a propofol target
blood concentration at 2 μg/ml using the target-
controlled infusion system, with maintenance doses of
remifentanil at 0.2–0.5 μg/kg/min and propofol at 2–
2.5 μg/ml. To facilitate endotracheal intubation using a
left-sided double lumen tube Broncho-Cath™ (Mallinck-
rodt Medical, Athlone, Ireland), 50 mg of rocuronium
bromide was administered. We did not administer add-
itional muscle relaxants except when a 10 mg mainten-
ance dose of rocuronium bromide was used just after
the patient was placed into the left lateral decubitus pos-
ition, and 20 mg rocuronium bromide was administered
just before the first incision. The train-of-four was mea-
sured for neuromuscular monitoring throughout the
operation. A central line was inserted in the right jugular
vein. The patient’s ABP and central venous pressure
(CVP) were continuously monitored using invasive
means. Electrocardiography showed the sinus rhythm
supported by the pacemaker, but the mode was changed
from DDD to DOO at the heart rate of 80 bpm to avoid
interference of electrocautery. Defibrillator pads were
attached because implantable cardioverter defibrillator
detection was inactivated. A transesophageal echocardi-
ography (TEE) probe was placed for monitoring the
Fig. 1 Chest radiograph. Chest radiograph showing the right-side
pneumothorax with a chest tube. LVAD: left ventricular assist device
Fig. 2 A computed tomography image of the chest in lung
window. Computed tomography showing the right-side
pneumothorax with moderately retained pleural effusion
Iwata et al. BMC Anesthesiology           (2020) 20:18 Page 2 of 7
performance of the LVAD and to determine intraopera-
tive cardiac function. Initial findings included severely
dilated left ventricle (LV) and right ventricle (RV), bow-
ing of the intraventricular septum into the RV (Fig. 3),
reduced LV and RV wall motion [RV-fractional area
change (FAC) 16.8%], severe mitral regurgitation, con-
tinuous closed aortic valves, no aortic regurgitation, and
trivial tricuspid regurgitation (TR) after TAP. The inflow
cannula, anastomosed to the apex of the LV, and the
outflow cannula, attached to the ascending aorta, of the
LVAD were unobstructed with low flow velocities of
90.2 cm/s and 87.3 cm/s on pulse wave and color Dop-
pler analyses, respectively. The right ventricular systolic
pressure (RVSP) was estimated at 21 mmHg by measur-
ing the TR jet maximum velocity. First, arterial gas ana-
lysis showed the following results: pH 7.437, pCO2 31.1
mmHg, pO2 225 mmHg, BEecf 2.7, lactate 0.7 mmol/L,
SaO2 99% and Hb 9.2 g/dL at FiO2 of 0.5.
When the patient was placed in the left lateral decubi-
tus position, the CVP increased from 12mmHg to 20
mmHg despite maintaining a mean ABP of 80 mmHg
(Fig. 4 (A)). The external portion of driveline was not
kinked. As the patient was coughing slightly, 10 mg
rocuronium bromide was administered, and the dose of
remifentanil was increased. TEE examination revealed
an almost akinetic LV, free wall RV, and a flattened in-
traventricular septum. The inflow and outflow cannulas
of the LVAD were noted to be in the proper position
with a pulsatile flow of approximately 60 cm/s and 110
cm/s, respectively. We assessed that the patient needed
inotropic support, and hence, the administration of do-
butamine (3.3 μg/kg/min) and milrinone (0.2 μg/kg/min)
was initiated. Gradually, the CVP returned to 12 mmHg,
and TEE showed improved LV and RV motions, with
rightward shift of the intraventricular septum. At the be-
ginning of OLV, the pressure-controlled ventilation mode
was adjusted; peak inspiratory pressure and positive end-
expiratory pressure were changed from 17 cmH2O to 28
cmH2O and from 5 cmH2O to 7 cmH2O, respectively, to
maintain saturation of percutaneous oxygen (SpO2) above
90%. After insertion of the access ports, SpO2 decreased
to 91% at FiO2 of 1.0, pump power consumption increased
to 3.5 watts, and the CVP reached 20mmHg, when the
mean ABP was maintained at approximately 85mmHg
(Fig. 4 (B)). TEE showed severely reduced RV motion, and
the intraventricular septum had again shifted slightly to
the left side. The RVSP was calculated at 35mmHg,
whereas the RV-FAC was calculated at 17.7% and ap-
peared to be near the pre-OLV level. For further support
of right heart function, continuous intravenous infusion of
milrinone was increased to 0.4 μg/kg/min. Arterial blood
gas analysis at this time revealed the following results: pH
7.357, pCO2 42.9mmHg, pO2 67.9mmHg, BEecf − 1.4,
lactate 0.6 mmol/L, SaO2 96.7% and Hb 10.2 g/dL at FiO2
1.0. After a couple of min, TEE examination showed that
the LV and RV motions had slightly improved, and the in-
traventricular septum had shifted toward the RV. Reflect-
ing gradually improved RV wall motion, the RV-FAC was
found to be 33.8%. With the increase in urine output, oxy-
genation improved and CVP decreased to 10mmHg. The
TEE findings did not change, and the mean ABP was
maintained at 64–85mmHg. The pulsatile waveforms
were maintained on ABP and SpO2 throughout the oper-
ation. Intraoperatively, the EVAHEART® monitor showed
that the pump speed was set at 1700 rpm; the pump
power consumption was 2–4W. The VATS was com-
pleted successfully with stable hemodynamic conditions.
Intraoperatively, the total administration of fentanyl
was 450 μg. For postoperative pain control, a single
intercostal nerve block (ICNB) was applied by the thor-
acic surgeons from the inside whilst closing the chest,
and an intravenous patient control system (fentanyl
20 μg/h, lock-out time 10min, 20 μg/one demanded
dose) was used. The total OLV time was 3 h 6min, with
an operation time of 3 h 5 min, necessitating a fluid in-
put of 1320 ml crystalloids. The total urine output and
blood loss measured were 2550 ml and 23ml, respect-
ively. Before recovery from general anesthesia, the TEE
findings and LVAD parameters showed unremarkable
changes in the supine position. The neuromuscular
blockade was reversed with sugammadex sodium. After
extubation, the patient did not experience pain and
could breathe deeply. The patient was transferred to the
intensive care unit in stable condition. However, he
needed temporary bilevel positive airway pressure
support after several hours. Moreover, postoperative
pneumonia was suspected on postoperative day 2, and a
change in the antibiotic protocol was needed. Finally, he
recovered in 1 week and was discharged from our hos-
pital in stable condition on postoperative day 37.
Fig. 3 A transesophageal echocardiographic image. Mid-esophageal
4-chamber view showing the severely dilated right and left
ventricles. The intraventricular septum was bowing into the
right ventricle
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Discussion and conclusions
For patients with LVAD, the right heart function is fre-
quently marginal; hence, it is important to avoid factors
that worsen PVR (e.g., hypoxia, hypercarbia, and light
anesthesia) and overfilling the RV with fluid [11–13].
However, OLV could lead to higher PVR, induced by
possible complications such as hypoxemia and hypercar-
bia, where the RV encounters sudden changes in after-
load, preload, and contractility [14]. Therefore, based on
the findings of previous studies [3–10], the management of
LVAD-supported patients for VATS may be more challen-
ging than that of LVAD-supported patients undergoing
noncardiac surgeries, as there may be sudden OLV-
associated, deteriorative RV function.
Generally, medical therapy for acute right heart failure
starts with meticulous volume optimization. Subsequent
management strategies involve inotropes to reduce the car-
diac filling pressures (dobutamine and phosphodiesterase
III inhibitors) and further measures for afterload reduction
[inhaled nitric oxide (iNO)] [15, 16]. NO is administered as
a pharmacological intervention to treat right heart failure
caused by pulmonary hypertension [15, 16]. However, it
remains controversial whether iNO is effective in hypoxia
during OLV. Therefore, routine use of iNO to treat hypox-
emia during OLV is not recommended [17, 18].
In our present case, relatively preserved right heart func-
tion (trivial TR and low CVP and RVSP) could tolerate an
increase in PVR caused by OLV-induced hypoxia with
administration of dobutamine and milrinone and/or ad-
justment of the ventilator.
In fluid therapy of a patient with LVAD undergoing non-
cardiac surgery, hypovolemia can compromise not only the
perfusion of vital organs but also LVAD performance,
although excessive fluid administration may lead to over-
load in the interstitial space, with increased pulmonary
complications, delayed recovery, hypoxia, induced pulmon-
ary hypertension, and right heart failure [12].
After LVAD implantation, the patient’s clinical course
was hemodynamically stable. However, it was difficult to
maintain the body weight constant due to excessive
urination caused by diuretic administration and high or
low intake of water, salt, and food. The body weight was
controlled by discontinuing the administration of di-
uretics and adjusting the intake of food, salt, and water.
However, pneumothorax recurred, and the body weight
was decreased by loss of appetite. Consequently, the patient
lost body weight preoperatively, and needed volume load to
avoid occurrence of the sucking phenomenon and thrombus
formation.
According to Shah et al., at left ventricular internal
diastolic dimension (LVIDD) 7 cm, the hazard ratio for
axial configuration device thrombosis, compared with
the centrifugal configuration device, was 1.61 and con-
tinued to rise as the LVIDD increased. It was considered
that the patient potentially had higher thrombotic risk
because the preoperative LVIDD of the patient was
Fig. 4 Anesthetic record. The pulsatile waveforms were maintained on ABP. When the patient was placed in the left lateral decubitus position,
CVP increased from 12mmHg to 20 mmHg (A). After insertion of the access ports, SpO2 decreased to 91% at FiO2 of 1.0, and the CVP reached
20mmHg, although the mean ABP was maintained at approximately 85 mmHg (B). ABP: arterial blood pressure, CVP: central venous pressure,
SpO2: saturation of percutaneous oxygen, FiO2: fraction of inspiratory oxygen, OLV: one-lung ventilation. X: start and completion of anesthesia,
◎: start and completion of surgery, ▽: intubation, △: extubation
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measured at 7.7 cm, although EVAHEART® is a centrifu-
gal LVAD. Conversely, in multivariable models, the haz-
ard of stroke was higher with the CC device regardless
of LVIDD [19]. In addition, interruption of anticoagula-
tion due to the bleeding risk associated with an elective
procedure may also lead to an elevated risk of thrombo-
embolism, even if heparin bridging is implemented. A
recent study recommended an extended personalized
approach that incorporates the extent of the patient’s
underlying risk for thrombosis and bleeding [20].
In LVAD patients, severe right heart failure is a throm-
botic risk factor [20] and may be induced by hypovolemia.
Therefore, preoperative volume management with anticoa-
gulation therapy is important to avoid thrombus formation.
Consequently, the patient had been hydrated with
crystalloids, and a weight gain of 3.5 kg in 4 days was
achieved before the VATS, exceeding his target body
weight by 1 kg, as the optimal volume management to
compensate for body weight loss. Hemodynamic stability
was achieved at anesthesia induction, although we had
to manage deteriorative desaturation during OLV. Finally,
the total fluid balance was minus 1253ml, and oxygen-
ation during OLV gradually improved, accompanied with
an increase in the volume of urine, which was drained
continuously.
EVAHEART®, i.e., the patient’s LVAD, acts as an im-
plantable centrifugal blood pump. It is used for bridge-
to-transplantation and has a gentle-slope pressure-flow
characteristic and an extremely high pump flow capacity
of 15–20 l/min during systole [21]. Continuous-flow
LVADs generate flow that may present pulsatility be-
cause of the residual LV function of the assisted heart.
Indeed, the presence of pulsatility on pump signals has
been used as an anecdotal “marker” of the myocardial
contractile state in the clinical realm [11, 21–24]. There-
fore, it is anticipated that the pump flow for patient
management does not need to be known if the pulsatility
is maintained on an arterial line and/or SpO2. Intraoper-
atively, in the present case, the pump flow pattern was
completely pulsatile at a constant speed of 1700 rpm,
with a stable pump power consumption at 2–4W.
Monitoring of CVP and pulmonary artery catheter
(PAC) placement should be considered on a case-by-case
basis [4, 12, 13]. In this case, we considered that a PAC
was not necessary because the patient showed no evidence
of pulmonary hypertension and his right heart function
was sufficiently preserved to resist the increase in PVR
associated with OLV. In addition, TEE was anticipated to
replace PAC because TEE can provide quantification of
pulmonary artery systolic pressure by the trans-tricuspid
pressure gradient, which is a reliable method compared to
PAC [15]. Practically, in conjunction with CVP, TEE was
useful to assess the deteriorative hemodynamic changes
following OLV and change in patient position and to
guide fluid therapy and inotropic drug administration.
However, PAC should be considered in cases of pulmon-
ary hypertension and/or highly predictable hemodynamic
instability during surgery because of progressive right
heart failure, for example, for a LVAD patient with low
PAP and high CVP [13] .
A change to the lateral decubitus position could also
possibly affect LVAD performance because of decrease in
preload [3, 12, 13]. In the current case, we suspected
insufficient anesthesia, as a change of the patient position
to the lateral decubitus position resulted in a transient
increase in PVR. In addition to rocuronium bromide and
remifentanil, dobutamine and milrinone were adminis-
tered to improve right heart function and LVAD perform-
ance. Eventually, hemodynamic stability was achieved.
Regarding postoperative analgesia, there is no gold
standard for regional analgesia for VATS. In contrast,
thoracic epidural analgesia and paravertebral block are
established analgesic gold standards for open surgery such
as thoracotomy [25]. Recently, several types of regional
analgesia have been reported for VATS such as multilevel
and single-shot paravertebral blocks, interpleural infusion,
long thoracic nerve block [25], retrolaminar block, erector
spinae plane block [26], and continuous and single-shot
serratus plane blocks [27]. These procedures may be ap-
plied even for LVAD patients who require anticoagulation.
However, no study has examined the frequency and sever-
ity of hemorrhagic complications after plexus or periph-
eral block in patients receiving anticoagulation therapy.
For patients undergoing deep plexus or deep peripheral
block, recommendations regarding neuraxial techniques
should be similarity applied [28].
In our case, for postoperative pain control, intravenous
patient-controlled analgesia with fentanyl was used and
a single shot of ICNB was applied by the thoracic sur-
geons before closing the chest; this was favored due to
the lower incidence of serious adverse events such as
epidural hematoma, despite poorer pain control than
that after thoracic epidural anesthesia [29].
The type of anesthesia (inhalational versus total intra-
venous anesthesia) by itself does not affect oxygenation
during OLV [14, 17], although intravenous anesthetic
drugs have a limited effect on hypoxic pulmonary vaso-
constriction, which is attenuated by inhaled anesthetics
[30]. Because the patient was diagnosed with Becker type
muscular dystrophy, we chose total intravenous anesthesia
to avoid the potential risk of malignant hyperthermia,
although controversial results have been reported regard-
ing whether malignant hyperthermia is caused by adminis-
tration of succinylcholine rather than volatile anesthetic
agents [31, 32]. We believe that it is not crucial to select
the type of anesthesia in LVAD patients that require OLV.
The anesthetic management of a patient with LVAD in
VATS is challenging because the possible hemodynamic
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changes induced by hypoxia associated with OLV affect
LVAD performance and right heart function.
In our experience, VATS that requires OLV will be
well tolerated in a patient with LVAD with preserved
right heart function, and a multidisciplinary approach to
maintain right heart function will be needed.
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